Brokerages expect that Flexion Therapeutics Inc (NASDAQ:FLXN) will post $1.29 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Flexion Therapeutics’ earnings, with estimates ranging from $900,000.00 to $1.68 million. The company is expected to announce its next earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Flexion Therapeutics will report full-year sales of $1.29 million for the current financial year, with estimates ranging from $900,000.00 to $1.68 million. For the next year, analysts forecast that the company will post sales of $25.45 million per share, with estimates ranging from $17.50 million to $41.70 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Flexion Therapeutics.
Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.09).
A number of equities research analysts recently weighed in on FLXN shares. Berenberg Bank started coverage on shares of Flexion Therapeutics in a report on Thursday, February 1st. They issued a “buy” rating and a $42.00 target price on the stock. Wells Fargo & Co set a $39.00 target price on shares of Flexion Therapeutics and gave the stock a “buy” rating in a report on Monday, October 30th. Zacks Investment Research lowered shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Royal Bank of Canada set a $44.00 target price on shares of Flexion Therapeutics and gave the stock a “buy” rating in a report on Sunday, October 29th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $99.11.
In other news, insider Neil Bodick acquired 2,700 shares of the firm’s stock in a transaction on Tuesday, November 21st. The stock was purchased at an average price of $24.49 per share, for a total transaction of $66,123.00. Following the purchase, the insider now owns 64,605 shares in the company, valued at approximately $1,582,176.45. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 15.98% of the company’s stock.
A number of large investors have recently bought and sold shares of FLXN. Advisor Group Inc. increased its stake in Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 3,500 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of Flexion Therapeutics during the 4th quarter worth approximately $108,000. SG Americas Securities LLC purchased a new stake in shares of Flexion Therapeutics during the 3rd quarter worth approximately $135,000. IFP Advisors Inc increased its stake in shares of Flexion Therapeutics by 58.1% during the 3rd quarter. IFP Advisors Inc now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $194,000 after purchasing an additional 2,950 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Flexion Therapeutics during the 3rd quarter worth approximately $235,000. Hedge funds and other institutional investors own 73.21% of the company’s stock.
Shares of Flexion Therapeutics (NASDAQ FLXN) opened at $22.54 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 12.93 and a quick ratio of 12.93. Flexion Therapeutics has a fifty-two week low of $16.51 and a fifty-two week high of $32.25. The firm has a market cap of $846.17, a PE ratio of -6.40 and a beta of 0.91.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/09/flexion-therapeutics-inc-flxn-expected-to-announce-quarterly-sales-of-1-29-million.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.